Medical Oncology

Uzm. Dr. Seval Akay

Doctor and researcher İzmir Şehir Hastanesi İzmir
Breast Neoplasms
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyMedical Oncologysaglik.gov.trFrom source
  • Institutionİzmir Şehir Hastanesisaglik.gov.trFrom source
  • Area of workBreast NeoplasmsExtracted from 4 publications · Model version —From source
  • Publications30 publicationsOpenAlex, ORCIDFrom source
  • ORCID0000-0002-1235-6739ORCIDFrom source
  • Last synchronised5 November 2026 09:07https://izmirsehir.saglik.gov.tr/TR-1046789/doktorlarimiz.html#seval-akaysaglik.gov.tr

Scientific work

Publications on Breast Neoplasms

30 publications

  1. Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study

    Current Oncology, 2026

    DOI 10.3390/curroncol33060365 PMID 42346265 Open-access full textSource: OpenAlex

  2. Impact of adjuvant endocrine therapy on disease-free survival in early triple-positive breast cancer: a multicenter retrospective cohort study of the Turkish oncology group

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-16667-y PMID 42693417 Open-access full textSource: OpenAlex

  3. Prognostic Impact of Cetuximab-Related Hypomagnesemia and Hypokalemia in RAS/RAF Wild-Type Colorectal Cancer: A Multicenter Study

    Cancer Management and Research, 2026

    DOI 10.2147/cmar.s570548 PMID 41930183 Open-access full textSource: OpenAlex

  4. Evaluation of Olaparib Efficacy Following CDK4/6 Inhibitor Therapy in BRCA-Mutated, Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Turkish Oncology Group (TOG) Study

    Targeted Oncology, 2026

    DOI 10.1007/s11523-026-01261-w PMID 42907609 Source: OpenAlex

  5. Clinicopathologic Features and Postoperative Outcomes of Parotidectomy: A 16-Year Retrospective Cohort Study from a Tertiary Referral Center

    Diagnostics, 2026

    DOI 10.3390/diagnostics16020216 PMID 41594192 2 citations (Europe PMC) Open-access full textSource: ORCID

  6. MCPH1 and DNA Damage Response Pathway Genes as Candidate Susceptibility Loci in Hereditary Breast Cancer

    Diagnostics, 2026

    DOI 10.3390/diagnostics16182967 PMID 42793752 Open-access full textSource: ORCID

  7. Comparison of Baseline Systemic Inflammatory Indicators in Preoperative Treatment of Gastric Carcinoma

    Preprints.org, 2026

    DOI 10.20944/preprints202607.0514.v1 Open-access full textSource: OpenAlex

  8. Threshold-Dependent Diagnostic Performance of Fine-Needle Aspiration Cytology in Parotid Tumors: A Milan System-Based Analysis

    Acta Cytologica, 2026

    DOI 10.1159/acy/abjag001 PMID 42671948 Source: OpenAlex

  9. Baseline Inflammatory and Nutritional Indices Show Limited Discrimination for Major Pathological Response and Survival After Neoadjuvant Chemotherapy for Gastric Cancer: A Retrospective Comparison of Eleven Indices

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15176893 PMID 42739899 Open-access full textSource: OpenAlex

  10. Comparison of Clinicopathological Characteristics for HER2-Null, HER2-Ultralow and HER2-Low Breast Cancer: A Single-Center Study

    Medicina, 2025

    DOI 10.3390/medicina61040719 PMID 40283010 6 citations (Europe PMC) Open-access full textSource: ORCID

View all 30 publications